只有肺部的转移性胰腺癌:患者特征,分子概况和生存率的差异
Alice Boilève1, Léa Mercier2, Baptiste Bonnet3
1Gustave Roussy, Département de Médecine Oncologique, Villejuif 94805, France; Université Paris Saclay, Villejuif 94805, France; Gustave Roussy, INSERM U1279, Villejuif 94805, France.
European journal of cancer (Oxford, England : 1990)
|January 17, 2026
概括
只有肺转移的胰腺管腺癌 (PDAC) 患者的整体存活率 (OS) 较好,女性更常见,KRAS突变较少. 这些发现表明PDAC肺转移具有独特的特征和潜在的更好的预后.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 医学研究 医学研究
背景情况:
- 胰腺管道腺癌 (PDAC) 的机体变性仍然不清楚,尽管有建议,只为肺部转移的更好的预后.
- 了解影响PDAC转移部位的生物学和临床因素对于患者的治疗结果至关重要.
研究的目的:
- 为了根据转移部位对比胰腺管道腺癌患者.
- 专门研究只有肺转移的患者的特征和预后.
主要方法:
- 在一个学术中心对转移性PDAC患者 (2010-2022) 的回顾性分析.
- 在转移性诊断时,仅肺转移的定义是孤立的肺参与.
- 在转移部位组之间对人口统计,临床和分子特征进行比较.
主要成果:
- 在1012名PDAC患者中,有11%的患者仅患有肺转移;这些患者往往是女性,在诊断时年龄较大,并且不太可能患有同步转移.
- 通过液体活检,在肺部组中观察到较低的ctDNA检测率,包括KRAS和TP53突变.
- 仅肺转移的平均整体存活期 (OS) 比仅肝转移 (13.5个月),仅腹转移 (11.5个月) 或其他部位 (11.3个月) 的平均总存活期 (28.7个月) 显著更高.
结论:
- 只有肺部PDAC转移的患者表现出更好的生存状况,独特的人口特征 (更多的女性) 和某些突变的较低率 (例如,KRAS).
- 这些发现支持具有特定特征的PDAC概念,特别是肺转移的更好的预后.
- 只有肺转移的局部治疗的潜力可能进一步改善结果,以及减少ctDNA检测.
相关概念视频
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:30Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...